Abstract
The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial was a landmark randomized controlled clinical trial in 11 140 type 2 diabetic patients from 215 centers in 20 countries with a two-by-two factorial design. In the blood pressure-lowering arm, patients were treated using a fixed combination of the ACE-inhibitor, perindopril, and the thiazide-like diuretic, indapamide, or placebo, whereas in the glucose-lowering arm, the intervention compared the sulphonylurea gliclazide plus other glucose-lowering drugs, targeting a glycated hemoglobin value of 6.5% or less, with standard glucose control. Primary end-points were major macro- and microvascular events in both arms. This review gives an overview of the results of the primary randomized trial, results from observational follow-up studies, and results of several biomarker studies and discusses the perspectives of these data in the context of recent major outcome trials for current medical treatment.
| Original language | English |
|---|---|
| Journal | Diabetes, Obesity and Metabolism |
| Volume | 22 |
| Issue | S2 |
| Pages (from-to) | 12-18 |
| Number of pages | 7 |
| ISSN | 1462-8902 |
| DOIs | |
| Publication status | Published - 2020 |
Keywords
- antidiabetic drug
- cardiovascular disease
- clinical trial
- diabetic nephropathy
- glycaemic control
- macrovascular disease